PIPELINE

Main projects in clinical development stages.

As of April 1, 2019
AnGes‐Origin Project (Drug)
Code /
Project Indication Area Development Stage
Dosage Form

JP Marketing approval acqured
HGF Plasmid Critical Limb Ischemia
AMG0001
（Beperminogene Injection
(Arteriosclerosis Obliterans
Perplasmid） & Buerger's Disease)
US Planning next steps

AMG0101
Atopic Dermatitis JP Phase 3 completed*  
Ointment
NF‐kB Decoy Oligonucleotide
AMG0101 Low Back Pain due to Disc 
US Phase 1b (ongoing)
Injection Degeneration

AGMG0201
DNA Vaccine Injection
Hypertension AU Phase 1 /2 (ongoing)

* The study did not show statistically significant difference between the NF‐κB Decoy Oligonucleotide treated group and the placebo group in the primary endpoint.

In‐Licensed Project
・CIN Therapeutic Vaccine [Licensed in development and marketing rights for Japan, US, UK and China from BioLeaders (South Korea) and 
sublicensed out to Morishita Jintan, Co.(JP)］
・DNA Vaccine Equine Polyclonal Antibody Therapy for Ebola virus [Vical, Inc. (US), development and marketing rights for Japan］

Alliance
Project Indication Area Partner

JP Mitsubishi Tanabe Pharma

Peripheral Arterial Diseases

HGF Plasmid
(Arteriosclerosis Obliterans US Mitsubishi Tanabe Pharma
(Beperminogene perplasmid)
& Buerger's Disease)

IL Kamada Ltd.

NF-κB Decoy Oligonucleotide Dermal Diseases World Shionogi